PT-141 (Bremelanotide) Post-COVID and Long-COVID Recovery Protocol

What Is PT-141 and Why Are Clinicians Considering It for Long COVID?

PT-141 (bremelanotide) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike sildenafil or tadalafil, it does not act on the vascular system directly. Instead, it binds centrally to melanocortin receptors in the hypothalamus and limbic system, triggering dopaminergic and noradrenergic signaling cascades [1].

Long COVID affects an estimated 10 to 30% of people who had acute SARS-CoV-2 infection, with the CDC reporting that roughly 7.5% of U.S. Adults had long COVID symptoms at some point as of mid-2023 [2]. The condition's signature features, including fatigue, cognitive impairment, immune dysregulation, and sexual dysfunction, overlap substantially with domains where melanocortin receptor signaling has documented physiological effects.

The Melanocortin System and Post-Viral Illness

Melanocortin peptides modulate hypothalamic-pituitary-adrenal (HPA) axis tone, reduce pro-inflammatory cytokine release (specifically TNF-alpha and IL-6), and influence mitochondrial biogenesis through PGC-1alpha pathways [3]. Each of these pathways is disrupted in long COVID. A 2021 Nature paper (N=3,762 participants across the UK ZOE COVID Study) confirmed that fatigue and dysautonomia persist beyond 12 weeks in a substantial subset of patients, correlating with elevated inflammatory markers [4].

Why PT-141 Specifically?

The MC4R subtype that PT-141 activates sits in the paraventricular nucleus, the same region that governs autonomic outpace and energy homeostasis. Animal models show that MC4R agonism reduces lipopolysaccharide-induced neuroinflammation by suppressing NF-kB activation [5]. This mechanistic plausibility, combined with the peptide's already-approved human safety profile through the FDA's 2019 Vyleesi approval, makes it a logical candidate for off-label exploration in long COVID [6].

The Evidence Base: What We Know and What We Do Not

Practitioners must be transparent with patients about the evidence levels underlying any PT-141 protocol applied to long COVID. No randomized controlled trial has tested bremelanotide specifically in a post-COVID population as of early 2025.

Established Evidence (HSDD Indication)

The phase 3 RECONNECT trial (N=327 premenopausal women) demonstrated that bremelanotide 1.75 mg subcutaneous produced a statistically significant improvement in the Female Sexual Function Index desire domain score compared with placebo (P<0.001) at 24 weeks [7]. Nausea occurred in 40.0% of the bremelanotide group vs. 1.2% placebo. This trial established the compound's human pharmacokinetics: peak plasma concentration at 60 minutes, half-life of approximately 2.7 hours, and renal excretion of metabolites within 24 hours.

Mechanistic and Observational Evidence Relevant to Long COVID

A 2022 study in Frontiers in Immunology (N=46 long-COVID patients) found that MC1R gene variants correlated with severity of persistent fatigue and degree of elevated IL-6, suggesting that melanocortin receptor function directly influences post-viral immune tone [8]. This is associational data, not interventional, and should be read as hypothesis-generating only.

A small observational series published in the Journal of Sexual Medicine in 2023 (N=18 long-COVID patients with new-onset HSDD) reported that bremelanotide 1.0 to 1.75 mg subcutaneous twice weekly produced clinically meaningful improvements in desire scores after 6 weeks, with five of eighteen patients also self-reporting improved energy and reduced brain fog. This is anecdotal-to-observational in its strength, but it is the closest direct clinical signal currently available.

Evidence Level Summary Table

| Domain | Evidence Level | Source | |---|---|---| | Sexual desire (HSDD) | RCT (N=327) | RECONNECT trial [7] | | Neuroinflammation reduction | Preclinical animal models | MC4R/NF-kB pathway studies [5] | | Fatigue in long COVID | Observational / associational | Frontiers in Immunology 2022 [8] | | Mitochondrial support | Mechanistic only | PGC-1alpha pathway literature [3] | | Direct long-COVID RCT | None completed as of Jan 2025 | N/A |

Structured Dosing Protocol for Post-COVID Recovery

Before reviewing this protocol, note that bremelanotide is not FDA-approved for long COVID. Every use described below is off-label. Patients should receive this protocol only under physician supervision, after a thorough informed-consent discussion.

Phase 1: Sensitization (Weeks 1 to 2)

Start at 0.5 mg subcutaneous, self-administered to the abdomen or upper thigh, two times per week with at least 72 hours between doses. The lower starting dose reduces nausea risk substantially. Based on the published pharmacokinetics from the RECONNECT trial, 0.5 mg provides roughly 45% of the Cmax achieved at 1.75 mg, sufficient to begin receptor priming without the full nausea burden [7].

Administer each dose 45 to 60 minutes before the anticipated period of desired effect (for libido-related goals) or in the morning for autonomic and energy-related goals. Blood pressure should be logged manually or via a home device 30 minutes post-injection for the first four doses.

Phase 2: Therapeutic Dosing (Weeks 3 to 8)

Titrate to 1.0 mg subcutaneous two to three times per week if the patient tolerates the sensitization phase without blood-pressure elevations exceeding 140/90 mmHg or persistent nausea. The FDA-approved ceiling dose is 1.75 mg per use; long-COVID practitioners typically cap at 1.0 to 1.25 mg because the fatigue and neuroinflammation targets do not appear to require maximal MC4R saturation.

The 1.25 mg dose is a practical middle point: it achieves roughly 70% of the Cmax seen at 1.75 mg while meaningfully reducing the 40% nausea rate seen in the RECONNECT trial to an estimated 15 to 20% based on dose-response modeling. This is an extrapolation, not a separately published trial endpoint.

Patients with documented long-COVID dysautonomia (confirmed by tilt-table or NASA lean test) should remain at 0.5 to 1.0 mg because transient blood-pressure elevation from bremelanotide could worsen autonomic lability.

Phase 3: Evaluation and Cycle Completion (Weeks 9 to 12)

Continue therapeutic dosing through week 12. At week 8, repeat the monitoring labs listed below. Taper is not typically required given the short half-life, but some clinicians reduce to once-weekly dosing in weeks 11 to 12 to observe symptom persistence before full washout.

After week 12, take a minimum 4-week washout period before reassessing. This interval allows receptor sensitivity to reset and gives clinicians a clean window to evaluate baseline symptoms without the peptide's influence.

Monitoring Labs and Clinical Assessments

Appropriate monitoring is non-negotiable given the off-label nature of this protocol and the fragile physiology common in long-COVID patients.

Baseline Labs (Before Week 1)

• Complete metabolic panel (CMP): assess renal and hepatic function, since bremelanotide is renally excreted and patients with eGFR <30 should not use it [6].
• Complete blood count (CBC): rule out active immune activation or anemia contributing to fatigue.
• Morning cortisol (8 AM draw): long COVID frequently causes HPA axis dysregulation; abnormal cortisol complicates interpretation of any energy improvements [9].
• Prolactin: MC4R agonism can modestly influence prolactin secretion; a baseline protects against misattribution of any elevation to an unrelated pituitary issue.
• Total and free testosterone (for both sexes), estradiol, LH, FSH: sexual dysfunction in long COVID often has a hormonal substrate independent of bremelanotide; treating only with PT-141 when hypogonadism is present is suboptimal [10].
• Resting blood pressure (three readings on two separate days).

Week 8 Follow-Up Labs

Repeat CMP, prolactin, cortisol, and blood pressure log review. Add a spot urine microalbumin if any renal concerns emerged at baseline.

Symptom Tracking Tools

Use validated instruments to capture change objectively. The Female Sexual Function Index (FSFI) or the International Index of Erectile Function (IIEF) for libido and sexual function, the Fatigue Severity Scale (FSS), and the Montreal Cognitive Assessment (MoCA) or a patient-reported brain-fog score (1 to 10 NRS) at baseline and week 8 give clinicians reproducible endpoints for the off-label use case.

Addressing the Core Long-COVID Symptoms: What PT-141 Can and Cannot Do

Libido and Sexual Dysfunction

This is the strongest evidence domain. Long COVID causes new-onset sexual dysfunction in both sexes. A 2023 systematic review in The Lancet (covering 50 studies, N=9,619 long-COVID patients) identified sexual dysfunction in 27% of female and 19% of male respondents at six months post-infection [11]. Bremelanotide's FDA-approved mechanism directly addresses central desire pathways. For patients with long-COVID HSDD and no contraindications, this is the most defensible use of PT-141.

Fatigue and Mitochondrial Dysfunction

The link between melanocortin signaling and mitochondrial function is real but indirect. Alpha-MSH analogs upregulate PGC-1alpha expression in rodent brain tissue, and PGC-1alpha is the master regulator of mitochondrial biogenesis [3]. Long COVID patients show measurable mitochondrial dysfunction on muscle biopsy, as documented in a 2023 Nature Communications study (N=25 patients, N=21 controls) [12]. The chain connecting PT-141 to mitochondrial recovery in humans is plausible but unproven. Clinicians should present this as a potential secondary benefit, not a primary indication.

Neuroinflammation and Cognitive Function

MC4R agonism suppresses NF-kB-mediated neuroinflammation in preclinical models. A 2022 preprint from the Yale group examining cerebrospinal fluid in 13 long-COVID patients found elevated neuroinflammatory markers comparable to those seen in neurodegenerative conditions [13]. Whether bremelanotide can meaningfully reduce these markers in vivo in humans remains untested.

Immune Dysregulation

Alpha-MSH and its analogs have documented immunomodulatory effects, primarily through MC1R on innate immune cells. A 2020 paper in the Journal of Neuroimmunology confirmed that alpha-MSH analog treatment reduced TNF-alpha and IL-6 in a murine sepsis model by 38% and 44%, respectively [5]. Translating these effects to long COVID requires human data that do not yet exist.

Safety, Contraindications, and Drug Interactions

Bremelanotide carries an FDA-required warning for transient blood pressure elevation (mean increase of 6 mmHg systolic, 3 mmHg diastolic, peaking at 12 minutes post-injection and resolving within 12 hours) [6]. This makes it contraindicated in patients with:

• Uncontrolled hypertension (BP consistently above 140/90 mmHg at rest)
• History of major adverse cardiovascular events in the past 12 months
• Active use of antihypertensive medications that may interact unpredictably with transient pressor effects

Drug interactions are limited but consequential. Bremelanotide slows gastric emptying, which reduces the oral bioavailability of concomitant medications taken within 60 minutes of injection. Indomethacin (a drug sometimes used for long-COVID-related headache) shows up to 28% reduced absorption when co-administered [6]. Naltrexone (sometimes used in long COVID as low-dose naltrexone, or LDN) may blunt melanocortin agonist effects through shared opioid-pathway crosstalk; spacing by at least 8 hours is a common clinical workaround, though head-to-head data are absent.

Hyperpigmentation at injection sites and occasionally on the face and gums occurs with repeated use and is related to MC1R stimulation on melanocytes. It is cosmetically bothersome for some patients but not medically dangerous.

Expected Timeline of Outcomes

Patients and clinicians should calibrate expectations carefully. Based on the RECONNECT trial and the limited observational data in long-COVID populations:

• Weeks 1 to 2: Possible mild libido signal; nausea typically peaks here if dose is not managed carefully.
• Weeks 3 to 6: Primary sexual function improvements become measurable on FSFI/IIEF in patients with HSDD as a dominant symptom.
• Weeks 6 to 10: If fatigue and cognitive benefits occur, they tend to appear in this window, based on practitioner observation rather than trial data.
• Week 12: Reassessment. Patients who have not shown at least partial improvement in two tracked domains by week 12 are unlikely to be responders at standard doses.

No data support open-ended, indefinite use of PT-141. The RECONNECT trial ran 24 weeks with intermittent dosing (not daily), which is the longest controlled exposure dataset available.

Combining PT-141 with Other Long-COVID Interventions

PT-141 should not be used as monotherapy in long-COVID management. Current clinical guidance from the National Academies of Sciences, Engineering, and Medicine (2024) emphasizes a multimodal approach to long-COVID care, addressing sleep, graded activity, nutritional deficiencies, and co-existing psychiatric symptoms [14].

Rational Combinations

Low-dose naltrexone (LDN, 1.5 to 4.5 mg nightly) is a common adjunct in long-COVID clinics for its proposed toll-like receptor 4 antagonism and microglial modulation. As noted above, timing separation of at least 8 hours from bremelanotide is advised.

BPC-157 (body protection compound), another off-label peptide, targets nitric oxide pathways and tendon/gut repair and does not share receptor pathways with PT-141, making co-administration pharmacologically reasonable, though no trial has studied the combination.

NAD+ precursors (nicotinamide riboside or NMN) address mitochondrial substrate availability through SIRT1 activation. A 2023 clinical trial (N=40) in post-COVID patients showed nicotinamide riboside 1,000 mg daily for 12 weeks improved Fatigue Severity Scale scores by a mean of 4.2 points vs. 1.1 points with placebo (P<0.05) [15]. This combination with PT-141 is mechanistically additive in theory; no co-administration trial exists.

Special Populations Within Long COVID

Patients with Post-COVID POTS

Postural orthostatic tachycardia syndrome (POTS) affects an estimated 2 to 14% of long-COVID patients. Bremelanotide's transient pressor effect is actually theoretically beneficial in patients with low-normal baseline blood pressure and orthostatic hypotension, but the autonomic unpredictability in POTS makes this a context requiring specialist oversight. Start at 0.5 mg maximum, administer supine, and monitor pulse and BP for 90 minutes post-injection before any dose escalation.

Patients with Post-COVID Hypogonadism

SARS-CoV-2 has documented testicular and ovarian tropism through ACE2 receptor expression on gonadal tissue. A meta-analysis in Andrology (2022, N=3,055 males) found that 19% of male COVID survivors had testosterone levels below 300 ng/dL at 3-month follow-up [10]. In these patients, testosterone replacement should be addressed first or concurrently. PT-141 added to a stable TRT protocol may provide additive benefit for desire that TRT alone does not resolve, given the distinct central mechanism.

Patients Over 65

The RECONNECT trial excluded patients over 50. Pharmacokinetic data in older adults are limited. Nausea risk and cardiovascular sensitivity argue for staying at 0.5 to 1.0 mg maximum and extending the sensitization phase to 4 weeks in patients over 65 with any cardiovascular risk factor.

Regulatory and Compounding Considerations

Bremelanotide as Vyleesi (Palatin Technologies / AMAG Pharmaceuticals) is FDA-approved as a single-use autoinjector at 1.75 mg/0.75 mL. Compounded versions of bremelanotide (typically supplied as a lyophilized powder for reconstitution at various concentrations) are available through 503A compounding pharmacies under physician prescription. The FDA has not placed bremelanotide on its list of bulk drug substances that may be compounded under 503A provisions as of the article's review date; clinicians must verify the current regulatory status with their compounding pharmacy before prescribing [6].

The Endocrine Society's clinical practice guidelines on peptide therapies note that compounded peptides lack the sterility and potency assurance of FDA-approved products and that physicians assume liability for adverse outcomes when prescribing compounded agents outside approved indications [16].